Eyeworld

® INDICATIONS AND USAGE ILEVRO ® (nepafenac ophthalmic suspension) 0.3% is a nonsteroidal, anti-infl ammatory prodrug indicated for the treatment of pain and infl ammation associated with cataract surgery. Dosage and Administration One drop of ILEVRO ® Suspension should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the fi rst 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. IMPORTANT SAFETY INFORMATION Contraindications ILEVRO ® Suspension is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs. Warnings and Precautions • Increased Bleeding Time – With some nonsteroidal anti- infl ammatory drugs including ILEVRO ® Suspension there exists the potential for increased bleeding time. Ocularly applied nonsteroidal anti-infl ammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. • Delayed Healing – Topical nonsteroidal anti-infl ammatory drugs (NSAIDs) including ILEVRO ® Suspension may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • Corneal Effects – Use of topical NSAIDs may result in keratitis. In some patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events. • Contact Lens Wear – ILEVRO ® Suspension should not be administered while using contact lenses. Adverse Reactions The most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5 to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. For additional information about ILEVRO ® Suspension, please refer to the brief summary of prescribing information on adjacent page. *With ILEVRO ® Suspension versus 24% to 32% with vehicle; P<0.05. 3 † Results from 2 randomized, multicenter, controlled, double-masked trials of adult patients undergoing cataract extraction. In Study 1, patients were randomized to receive either ILEVRO ® Suspension (n=851), NEVANAC ® Suspension (n=845), ILEVRO ® Suspension vehicle (n=211), or NEVANAC ® Suspension vehicle (n=213). In Study 2, patients were randomized to receive either ILEVRO ® Suspension (n=540) or ILEVRO ® Suspension vehicle (n=268). 2,3 ‡ 84% to 86% with ILEVRO ® Suspension versus 38% to 46% with vehicle; P<0.05. 3 § This offer is not valid for patients who are enrolled in Medicare Part D, Medicaid, Medigap, VA, DOD, Tricare, or any other government-run or government-sponsored health care program with a pharmacy benefi t. Additional eligibility terms apply. See copay savings material for specifi c details. References: 1. IMS Health Xponent, January 2015-December 2015. Accessed December 2015. 2. Data on fi le. 3. Ilevro [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2014. 4. Fingertip Formulary, October 2015 (estimate derived from information used under license from Fingertip Formulary, LLC, which expressly reserves all rights, including rights of copying, distribution and republication). Prescribed Branded Ophthalmic NSAID 1 # 1 WHEN TREATING INFLAMMATION AND PAIN IN YOUR CATARACT SURGERY PATIENTS POTENCY, PRECISELY WHERE YOU NEED IT ILEVRO ® Suspension offers proven effi cacy, once-daily postoperative dosing, and affordable access for your patients 2-4 1x DAILY POSTOPERATIVE D O S I N G R E G I M E N 3 • ILEVRO ® Suspension should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the fi rst 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery 3 • Use of ILEVRO ® Suspension more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events 3 INFLAMMATION C O M P L E T E L Y C L E A R E D I N 2 O U T O F 3 PATIENTS AT DAY 14 2,3 * † O C U L A R PA I N C O M P L E T E L Y R E S O L V E D I N > 80% OF PATIENTS AT DAY 14 3 †‡ To learn more about treating postoperative infl ammation and pain with ILEVRO ® Suspension, visit myalcon.com/ilevro B R O A D COVERAG E 4 ELIGIBLE COMMERCIAL P A T I E N T S M A Y P A Y A S L I T T L E A S $ 35 OUT OF POCKET § © 2016 Novartis 04/16 US-ILV-16-E-0586

• Blank Page
• Blank Page (1)